A Study of Filgotinib in Korean Participants With Rheumatoid Arthritis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

PHASE4

Total Enrollment

118 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-10-22

Study Completion Date

2026-03-19

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary purpose of this study is to assess the percentage of participants achieving an American College of Rheumatology (ACR) 20 percent (%) Improvement (ACR20) response at Week 12 of the administration of the investigational product.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Filgotinib Effect on Proteomic Profile and Micro-RNA Expression in Patients With Active Rheumatoid Arthritis (RA)

NCT06527534

Rheumatoid Arthritis

RECRUITING PHASE4

Filgotinib Versus Placebo in Adults With Active Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Biologic Disease-modifying Anti-rheumatic Drug(s) (DMARDs) Treatment

NCT02873936

Rheumatoid Arthritis

COMPLETED PHASE3

Filgotinib in Combination With Methotrexate in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate

NCT02889796

Rheumatoid Arthritis

COMPLETED PHASE3

Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Have an Inadequate Response or Are Intolerant to Biologic DMARD Therapy

NCT04115839

Psoriatic Arthritis

TERMINATED PHASE3

Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With Rheumatoid Arthritis

NCT03025308

Rheumatoid Arthritis

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Rheumatoid Arthritis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Filgotinib Maleate 100 or 200 milligram

Group Type EXPERIMENTAL

Filgotinib Maleate

Intervention Type DRUG

Administered as oral tablets.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Filgotinib Maleate

Administered as oral tablets.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Jyseleca

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Participants who voluntarily provided written consent to participate in this study
2. Male or female, aged greater than or equal to (\>=) 19 years at the time of written informed consent
3. Participants diagnosed with rheumatoid arthritis according to the 2010 ACR/ European League Against Rheumatism (EULAR) classification criteria and who have an ACR functional class of I to III
4. Participants who meet the following criteria are eligible for the specified treatment protocol; those who have been treated with two or more type types (including MTX) of Disease-Modifying Antirheumatic Drugs (DMARDs) for at least 6 months (at least 3 months each) but have experienced insufficient therapeutic effects or have had to discontinue treatment due to adverse events of these medications (However, in cases where MTX is contraindicated due to conditions such as liver disease or renal failure, the participant must have been treated with at least two types of DMARDs, excluding MTX).

* Furthermore, in participants over 65 years of age, those at high risk of cardiovascular diseases, and those with a potential risk of malignancy, this protocol applies if they have not adequately responded to or tolerated conventional therapies, including Tumor Necrosis Factor (TNF) inhibitors or other biologic agents. Eligibility is confirmed if one of the following criteria is met:

1. DAS28 score exceeding 5.1.
2. DAS28 score between 3.2 and 5.1, with diagnostic imaging showing progression of joint damage.

Exclusion Criteria

1. Participants with hypersensitivity reactions to the active ingredient or other components of the investigational product
2. Participants with serious infections (for example \[e.g.\], sepsis) or active infections including localized infections
3. Participants with active tuberculosis (TB)
4. Participants with severe hepatic impairment (e.g., Child-Pugh C)
5. Participants with end-stage renal disease (\<creatinine clearance \[CrCl\] 15 milliliters per minute \[mL/min\])
6. Participants with absolute neutrophil count (ANC) \<1\*10\^9 cells per liter (/L)
7. Participants with absolute lymphocyte count (ALC) \<0.5\*10\^9 cells/L
8. Participants with hemoglobin \<8 grams per deciliter (g/dL)
9. Pregnant or lactating women
10. Women of childbearing potential who are not willing to consent to using effective contraception
11. Participants with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicinal product
12. Participants who received Janus kinase (JAK) inhibitors for the treatment of rheumatoid arthritis
13. Participants who have participated in other clinical studies for investigational product/medical device within 4 weeks prior to screening
14. Participants in whom the administration of Jyseleca Tablet is contraindicated according to the product label approved in Korea or based on certain medical conditions that have been identified in previous clinical studies
15. Participants for whom follow-up deems impossible

Minimum Eligible Age

19 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No